Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

May 24, 2018

Study Completion Date

December 31, 2022

Conditions
Breast CancerBreast TumorsCancer of Breast
Interventions
DRUG

Metformin

"Metformin is an oral diabetes medicine that helps control blood sugar levels.~Dosage/Frequency: 1500 mg per day: divided 500 mg in the morning and 1000 mg in the evening~Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes."

DRUG

Atorvastatin

"Atorvastatin is in a group of drugs called statins. Atorvastatin reduces levels of bad cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood while increasing levels of good cholesterol (high-density lipoprotein, or HDL).~Dosage/Frequency: 80 mg once a day at bedtime~Atorvastatin is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors."

PROCEDURE

Breast surgery

(Non-experimental) Female subjects with histologically-confirmed operable invasive breast cancer or DCIS will undergo core needle biopsy with a plan of surgical excision.

Trial Locations (1)

10032

Columbia University Medical Center - Herbert Irving Cancer Center, New York

All Listed Sponsors
lead

Columbia University

OTHER

NCT01980823 - Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer | Biotech Hunter | Biotech Hunter